Abstract
COVER : Zhang et al . found that fibroblast growth factor 21 (FGF21) increases the sensitivity of hepatocellular carcinoma (HCC) to sorafenib (SORA) by enhancing the phosphorylation of Smad3 through the phosphatidylinositol 3‐kinase/protein kinase B pathway under hypoxia, providing the possibility of combination therapy for SORA and FGF21 on HCC. See pages 99–112 for details.
EUVIMED